Background:  The study aims to collect real-world data on treatment patterns and decision points for treatment in patients with coronary artery disease (CAD) and/ or peripheral artery disease (PAD) treated with rivaroxaban 2.5 mg [twice daily] for the prevention of major cardiovascular events in adult patients with CAD at high risk of ischemic events and/ or documented PAD and to describe outcomes of an antithrombotic regime based on dual pathway inhibition (vascular dose of rivaroxaban 2.5 mg [twice daily] plus low-dose ASA [once daily]) across the broad range of patient risk profiles encountered in routine clinical practice. Sponsor:  Bayer Trial Registration No: NCT03746275 (clinicaltrials.gov) Link  Trial Status: recruiting  Enrolling Centers:  Worldwide: 10000 Participants Core Study Team: 
© Christian Mueller, 2012 - 2019 │  Disclaimer  │  Imprint  │  Webmaster │ Last Update: November 2019
Home News Team Studies Publications Events Cooperations Contact Dr. Ina-Maria Ferel-Harwerth Prof. Christian Müller Prof. Otmar Pfister Dr. Thilo Burkard